Literature DB >> 8120703

Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials.

R M Rosenfeld1, J E Vertrees, J Carr, R J Cipolle, D L Uden, G S Giebink, D M Canafax.   

Abstract

OBJECTIVE: To reconcile conflicting published reports concerning the absolute and comparative clinical efficacy of antimicrobial drugs for acute otitis media in children. STUDY SELECTION: Articles were identified by MEDLINE search, Current Contents, and references from review articles, textbook chapters, and retrieved reports. Randomized, controlled trials of therapeutic antimicrobial drugs used in the initial empiric therapy for simple acute otitis media were selected by independent, blinded observers, and scored on 11 measures of study validity. Thirty English and three foreign-language articles met all inclusion criteria. DATA EXTRACTION: Data were abstracted for an end point of complete clinical resolution (primary control), exclusive of middle ear effusion, within 7 to 14 days after therapy started. DATA SYNTHESIS: The spontaneous rate of primary control--without antibiotics or tympanocentesis--was 81% (95% confidence interval, 69% to 94%). Compared with placebo or no drug, antimicrobial therapy increased primary control by 13.7% (95% confidence interval, 8.2% to 19.2%). No significant differences were found in the comparative efficacy of various antimicrobial agents. Extending antimicrobial coverage to include beta-lactamase-producing organisms did not significantly increase the rates of primary control or resolution of middle ear effusion. Pretreatment tympanocentesis was positively associated with individual group primary control rates, negatively associated with the ability to detect differences in clinical efficacy and unassociated with resolution of MEE.
CONCLUSIONS: Antimicrobial drugs have a modest but significant impact on the primary control of acute otitis media. Treatment with beta-lactamase-stable agents does not increase resolution of acute symptoms or middle ear effusion; initial therapy should be guided by considerations of safety, tolerability, and affordability, and not by the theoretical advantage of an extended antibacterial spectrum.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120703     DOI: 10.1016/s0022-3476(94)70356-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  55 in total

Review 1.  Acute otitis media.

Authors:  P O'Neill
Journal:  BMJ       Date:  1999-09-25

2.  Current Concepts of Therapy for Otitis Media.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  alpha Streptococci and recurrences of otitis media. Right choice of antibiotic can decrease risk of recurrence.

Authors:  V P Joki-Erkkilä; J Pukander
Journal:  BMJ       Date:  2001-06-23

Review 4.  Acute otitis media.

Authors:  S Pirozzo; C Del Mar
Journal:  West J Med       Date:  2001-12

5.  Do we need to treat otitis media?

Authors:  S Chaudhary
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

6.  Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years.

Authors:  R A Damoiseaux; F A van Balen; A W Hoes; T J Verheij; R A de Melker
Journal:  BMJ       Date:  2000-02-05

7.  Management of acute otitis media.

Authors:  S Forgie; G Zhanel; J Robinson
Journal:  Paediatr Child Health       Date:  2009-09       Impact factor: 2.253

8.  Antibiotic management of acute otitis media.

Authors: 
Journal:  Paediatr Child Health       Date:  1998-07       Impact factor: 2.253

9.  Does a paediatric after-hours clinic use evidence-based guidelines in the management of acute otitis media?

Authors:  Jonathon L Maguire; Jane Healey; Hartley Garfield; Patricia C Parkin
Journal:  Paediatr Child Health       Date:  2003-09       Impact factor: 2.253

Review 10.  [Acute otitis media in children: antibiotic therapy or watchful waiting?].

Authors:  P Amrhein; A Hospach; C Sittel; A Koitschev
Journal:  HNO       Date:  2013-05       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.